Related Experiment Videos
Once-daily ceftriaxone therapy for serious bacterial infections in children
Insights
Ceftriaxone, a potent antibiotic, demonstrated safety and efficacy in treating pediatric bacterial infections at a 50 mg/kg daily dose. This regimen proved effective for outpatient antibiotic therapy and challenging intravenous access cases.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Bacteriology
Background:
- Bacterial infections are a common concern in pediatric populations.
- Effective and safe antibiotic treatments are crucial for children.
- Ceftriaxone is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftriaxone in treating nonmeningitic bacterial infections in children.
- To assess ceftriaxone plasma levels in pediatric patients receiving a single daily dose.
- To determine the suitability of ceftriaxone for outpatient pediatric antibiotic therapy.
Main Methods:
- A cohort of 35 children with various bacterial infections received ceftriaxone at 50 mg/kg daily.
- Clinical responses were monitored.
- Plasma ceftriaxone concentrations were measured at peak and trough levels.
- Minimum Inhibitory Concentrations (MICs) of infecting organisms were compared to trough levels.
Main Results:
- A satisfactory clinical response was observed in 33 out of 35 patients.
- Trough ceftriaxone levels exceeded the MIC for most infecting organisms, including Staphylococcus aureus.
- Ceftriaxone was generally well-tolerated, with no major adverse events reported.
Conclusions:
- Ceftriaxone is a safe and effective antibiotic for treating pediatric bacterial infections when administered as a single daily dose of 50 mg/kg.
- This dosing regimen is particularly advantageous for outpatient settings and patients with difficult intravenous access.
- Ceftriaxone offers a viable treatment option for a range of pediatric bacterial pathogens.
Abstract:
Ceftriaxone administered as a single daily dose of 50 mg/kg was evaluated in the treatment of 35 children with a variety of nonmeningitic bacterial infections. In two of the patients, the drug was discontinued before the response to the drug could be evaluated. All of the remaining patients had a satisfactory response. In 22 of the patients, plasma was available for the determination of ceftriaxone levels 1 h after a dose and immediately before the next dose. All but one of these patients had trough ceftriaxone levels which exceeded the MIC of the infecting organism, although marginally so for Staphylococcus aureus. Ceftriaxone appears to be safe and effective in the treatment of a variety of bacterial pathogens in children when administered at a single daily dose of 50 mg/kg. This drug may be especially useful in those patients in whom outpatient antibiotic therapy is contemplated or in whom maintenance of intravenous access is difficult.